Tag: thrombosis
Thromboinflammation and Antithrombotics in COVID-19
Thrombotic complications of SARS-CoV-2 infection were recognized early in the pandemic, when infected patients often presented with abnormal coagulation findings and acute macrovascular obstruction, and evidence of pulmonary... read more
Anticoagulation in COVID-19 Patients
Clinical, laboratory, and autopsy findings support an association between COVID-19 and thromboembolic disease. Acute COVID-19 infection is characterized by mononuclear cell reactivity and pan-endothelialitis, contributing... read more
Ascending Aortic Thrombus After COVID-19 Infection
SARS-CoV-2 predisposes patients to both venous and arterial thromboembolism, including ascending aortic thrombus. The current guidelines for anticoagulation recommend three to six months of continuous anticoagulation... read more
Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia
Vaccine-induced immune thrombotic thrombocytopenia is a serious complication of vaccination that is not feasible to anticipate or prevent. When the patient presents with sustained headache, neurologic symptoms/signs,... read more
A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children
Using the multicenter Children’s Hospital-Acquired Thrombosis registry, we identified five independent risk factors for hospital-acquired venous thromboembolism in critically ill children, deriving a new hospital-acquired... read more
Subclavian vs. Femoral Arterial Cannulations During ECMO
During peripheral extracorporeal veno-arterial membrane oxygenation (VA-ECMO) support, subclavian arterial cannulation provides, in comparison to femoral arterial cannulation, an anterograde flow which may prevent from left... read more
Anticoagulation in COVID-19
Thrombotic complications (arterial and venous) are common in patients admitted to hospital with COVID-19 and are an independent predictor of poor outcome. Microvascular thrombi also contribute to organ dysfunction, including... read more
Obesity, Inflammatory and Thrombotic Markers, and Major Clinical Outcomes in Critically Ill Patients with COVID-19 in the US
In critically ill patients with COVID-19, higher BMI was not associated with death or thrombotic events but was associated with a greater risk of ARDS and AKI-RRT. The lack of an association between BMI and circulating... read more
ARDS and High Blood Endocan Profile During COVID‑19
With great interest, we read the recently published paper by Pascreau et al. concluding that a high blood endocan profile during COVID‑19 distinguishes moderate from severe acute respiratory distress syndrome (ARDS). In... read more
Outcomes of Catheter-Related Arterial and Venous Thrombosis After Enoxaparin Therapy in Neonates and Infants With Congenital Heart Disease
A high proportion of vascular catheter-related thrombi identified in infants with congenital heart disease resolve with enoxaparin treatment. In all patients with thrombosis, arterial versus venous thrombosis is associated... read more
Longitudinal Respiratory Subphenotypes in COVID-19 Patients with ARDS
COVID-19-related ARDS has no consistent respiratory subphenotype. Patients diverged from a fairly homogenous to a more heterogeneous population, with trajectories of ventilatory ratio and mechanical power being the most discriminatory.... read more
Venous Thromboembolism Prophylaxis in Critically Ill Adults
Among critically ill adults, compared to control, low molecular weight heparin (LMWH) reduces incidence of deep venous thrombosis (DVT) while UFH and mechanical compressive devices may reduce risk of DVT. LMWH is probably... read more
Therapeutic Anticoagulation vs. Usual Care in Noncritically Ill COVID-19 Patients
Among noncritically ill patients with COVID-19 infection, therapeutic anticoagulation with heparin improved the proportion of patients who survived without need for organ support. Therapeutic anticoagulation was associated... read more
Effects of Early Mobilization on the Prognosis of Critically Ill Patients
Early mobilization was effective in enhancing the recovery of critically ill patients, but more large-scale, multicenter randomized controlled trials are required to further confirm these findings. A total of 39 articles... read more
Thrombosis vs. Hemorrhage Rates in Patients with Severe Respiratory Failure Due to COVID-19
Significant rates of pulmonary thromboembolism and of catheter-associated deep vein thrombosis were seen in both viral infections but were greater in those requiring the use of extracorporeal membrane oxygenation in coronavirus... read more
Impact of Marijuana on Venous Thromboembolic Events
Tetrahydrocannabinoids (THC) exposure increases the risk of TEC in patients with trauma. Early identification and treatment for TEC is required to improve outcomes in this high-risk subset of trauma patients. We performed... read more
Relationship between admission coagulopathy and prognosis in children with TBI
We concluded that admission APTT > 39.2 s and fibrinogen ≤ 120 mg/dL were independently associated with mortality in children with moderate to severe TBI. Early identification and intervention of abnormal APTT and... read more
Subarachnoid Hemorrhage in the Emergency Department
Subarachnoid hemorrhages (SAH) are frequently misdiagnosed; therefore, we believe it is imperative to address the diagnosis and initiation of early management in the emergency medicine department to minimize poor outcomes... read more
Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Johnson & Johnson Vaccination
The initial 12 US cases of Cerebral Venous Sinus (CVST) with thrombocytopenia after Ad26.COV2.S (Janssen/Johnson & Johnson) vaccination represent serious events. This case series may inform clinical guidance as Ad26.COV2.S... read more
Understanding The Links Between COVID-19 Vaccines and Thrombosis
The Advisory Committee on Immunization Practices (ACIP) is convening an emergency meeting to discuss adverse events that recently led to thrombotic events in 6 women administered the Johnson & Johnson COVID-19 vaccine in... read more
Vaccine-Induced Prothrombotic Immune Thrombocytopenia After AstraZeneca COVID-19 Vaccination
The United Kingdom, European Union, and Scandinavian countries have reported that the AstraZeneca COVID-19 vaccine appears to be associated with rare cases of serious blood clots, including blood clots in the brain. These... read more
